ArticleBiologics : targets & therapy2009
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.
Article in Biologics : targets & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Rare tongue base metastasis from SMARCA4-deficient undifferentiated non-small cell lung carcinoma: a case report.International journal of clinical and experimental pathology · 2026Article
- Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.Frontiers in pharmacology · 2026Article
- Entrectinib as first-lineTranslational lung cancer research · 2024Article
- Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform.PeerJ · 2024Article
- First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.Translational lung cancer research · 2023Article
- Simulation education utilizing phantom and angle reference guide in pulmonary nodule CT localization.Heliyon · 2023Article
- First-line tremelimumab plus durvalumab and chemotherapyFrontiers in pharmacology · 2023Article
- LobectomyAnnals of translational medicine · 2021Article
- Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua.Molecular genetics & genomic medicine · 2020Article
- Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.BMJ open · 2020Article
- Enhanced monoacylglycerol lipolysis by ABHD6 promotes NSCLC pathogenesis.EBioMedicine · 2020Article
- Article
- Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model.Scientific reports · 2018Article
- Crizotinib, an Effective Agent inClinical medicine insights. Case reports · 2018Article
- The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2017Review
- Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.Journal of aerosol medicine and pulmonary drug delivery · 2017Article
- Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer.Cancer medicine · 2016Review
- Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells.Journal of biomedical science · 2015Article
- Automated tumor analysis for molecular profiling in lung cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human - mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.
Indexed as
Identifiers
19707410PMC2726075W2067630223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.